{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T12:16:56Z","timestamp":1791548216652,"version":"4.3.4"},"reference-count":28,"publisher":"BMJ","issue":"11","content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Open"],"accepted":{"date-parts":[[2014,9,11]]},"published-print":{"date-parts":[[2014,11]]},"abstract":"<jats:sec><jats:title>Objective<\/jats:title><jats:p>To estimate isotretinoin exposure in Dutch pregnant women despite the implemented pregnancy prevention programme (PPP) and second, to analyse the occurrence of adverse fetal or neonatal outcomes in these isotretinoin exposed pregnancies.<\/jats:p><\/jats:sec><jats:sec><jats:title>Design<\/jats:title><jats:p>Population-based study.<\/jats:p><\/jats:sec><jats:sec><jats:title>Setting<\/jats:title><jats:p>The Netherlands.<\/jats:p><\/jats:sec><jats:sec><jats:title>Participants<\/jats:title><jats:p>A cohort of 203\u2005962 pregnancies with onset between 1 January 1999 and 1 September 2007 consisting of 208\u2005161 fetuses or neonates.<\/jats:p><\/jats:sec><jats:sec><jats:title>Main outcome measures<\/jats:title><jats:p>Isotretinoin exposure in the 30\u2005days before or during pregnancy. Proportions of adverse fetal or neonatal outcomes, defined as intrauterine deaths \u226516\u2005week of gestation and neonates with major congenital anomalies. ORs with 95% CIs adjusted for maternal age were calculated to estimate the risk of adverse fetal or neonatal outcome after maternal isotretinoin exposure.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>51 pregnancies, 2.5 (95% CI 1.9 to 3.3) per 10\u2005000 pregnancies, were exposed to isotretinoin despite the pregnancy prevention programme. Forty-five of these pregnancies, 2.2 (95% CI 1.6 to 2.9) per 10\u2005000 pregnancies, were exposed to isotretinoin during pregnancy and six additional women became pregnant within 30\u2005days after isotretinoin discontinuation. In 60% of isotretinoin exposed pregnancies, women started isotretinoin while already pregnant. In five out of the 51 isotretinoin exposed pregnancies (53 fetuses), 9.4% (95% CI 1.3% to 17.6%), had an adverse fetal or neonatal outcome. The OR for adverse fetal or neonatal outcomes after isotretinoin exposure in 30\u2005days before or during pregnancy was 2.3 (95% CI 0.9 to 5.7) after adjustment for maternal age.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>Although a PPP was already implemented in 1988, we showed that isotretinoin exposed pregnancies and adverse fetal and neonatal events potentially related to the exposure still occur. These findings from the Netherlands add to the evidence that there is no full compliance to the isotretinoin PPP in many Western countries. Given the limited success of iPLEDGE, the question is which further measures are able to improve compliance.<\/jats:p><\/jats:sec>","DOI":"10.1136\/bmjopen-2014-005602","type":"journal-article","created":{"date-parts":[[2014,11,13]],"date-time":"2014-11-13T04:19:36Z","timestamp":1415852376000},"page":"e005602","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":43,"title":["Isotretinoin exposure during pregnancy: a population-based study in The Netherlands"],"prefix":"10.1136","volume":"4","author":[{"given":"Ingeborg M","family":"Zomerdijk","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rikje","family":"Ruiter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leanne M A","family":"Houweling","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ron M C","family":"Herings","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miriam C J M","family":"Sturkenboom","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sabine M J M","family":"Straus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bruno H","family":"Stricker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2014,11,12]]},"reference":[{"key":"2024051512280951000_4.11.e005602.1","unstructured":"European Medicines Agency (EMA). Annex I of the Summary information on a referral opinion following an arbitration pursant to article 29 of directive 2001\/83\/EC for isotretinoin. 2003. http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/Referrals_document\/Isotretinoin_29\/WC500010881.pdf (accessed 2 May 2013)."},{"key":"2024051512280951000_4.11.e005602.2","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1016\/S0140-6736(83)90538-X","article-title":"Teratogenicity of isotretinoin","volume":"2","author":"Rosa","year":"1983","journal-title":"Lancet"},{"key":"2024051512280951000_4.11.e005602.3","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM198510033131401"},{"key":"2024051512280951000_4.11.e005602.4","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.0030483"},{"key":"2024051512280951000_4.11.e005602.5","doi-asserted-by":"publisher","DOI":"10.1007\/s00404-009-1112-2"},{"key":"2024051512280951000_4.11.e005602.6","doi-asserted-by":"crossref","first-page":"659","DOI":"10.2165\/11536250-000000000-00000","article-title":"Isotretinoin exposure during pregnancy: assessment of spontaneous reports in France","volume":"33","author":"Autret-Leca","year":"2010","journal-title":"Drug Saf"},{"key":"2024051512280951000_4.11.e005602.7","doi-asserted-by":"crossref","first-page":"27","DOI":"10.2165\/11595570-000000000-00000","article-title":"Implementation of the harmonized EU isotretinoin Pregnancy Prevention Programme: a questionnaire survey among European regulatory agencies","volume":"35","author":"Crijns","year":"2012","journal-title":"Drug Saf"},{"key":"2024051512280951000_4.11.e005602.8","doi-asserted-by":"publisher","DOI":"10.2165\/11319190-000000000-00000"},{"key":"2024051512280951000_4.11.e005602.9","doi-asserted-by":"crossref","first-page":"1060","DOI":"10.1002\/pds.3200","article-title":"Prescriptive contraceptive use among isotretinoin users in the Netherlands in comparison with non-users: a drug utilisation study","volume":"21","author":"Crijns","year":"2012","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"2024051512280951000_4.11.e005602.10","doi-asserted-by":"publisher","DOI":"10.1136\/jech.46.2.136"},{"key":"2024051512280951000_4.11.e005602.11","unstructured":"WHO Collaborating Centre for Drug Statistics Methodology. Anatomical Therapeutic Chemical (ATC) index with Defined Daily Doses (DDDs). http:\/\/www.whocc.no\/atc_ddd_index\/ (accessed 4 Oct 2013)."},{"key":"2024051512280951000_4.11.e005602.12","unstructured":"Stichting Perinatale Registratie Nederland. Grote Lijnen 10 jaar Perinatale Registratie Nederland. Utrecht: Stichting Perinatale Registratie Nederland, 2011."},{"key":"2024051512280951000_4.11.e005602.13","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.jpeds.2012.12.014","article-title":"First year of life medication use and hospital admission rates: premature compared with term infants","volume":"163","author":"Houweling","year":"2013","journal-title":"J Pediatr"},{"key":"2024051512280951000_4.11.e005602.14","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1517\/14740338.2013.745850","article-title":"Healthcare professional surveys to investigate the implementation of the isotretinoin Pregnancy Prevention Programme: a descriptive study","volume":"12","author":"Crijns","year":"2013","journal-title":"Expert Opin Drug Saf"},{"key":"2024051512280951000_4.11.e005602.15","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2125.2006.02837.x"},{"key":"2024051512280951000_4.11.e005602.16","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1016\/S0151-9638(05)79302-9","article-title":"Isotretinoin: compliance with recommendations in childbearing women","volume":"132","author":"Bensouda-Grimaldi","year":"2005","journal-title":"Ann Dermatol Venereol"},{"key":"2024051512280951000_4.11.e005602.17","doi-asserted-by":"crossref","first-page":"1251","DOI":"10.1002\/pds.3481","article-title":"Concomitant use of isotretinoin and contraceptives before and after iPledge in the United States","volume":"22","author":"Pinheiro","year":"2013","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"2024051512280951000_4.11.e005602.18","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2010.09.017"},{"key":"2024051512280951000_4.11.e005602.19","unstructured":"Stichting Perinatale Registratie Nederland. Grote Lijnen 1999\u20132012. Urecht: Stichting Perinatale Registratie Nederland, 2013."},{"key":"2024051512280951000_4.11.e005602.20","unstructured":"Roaccutane Summary of Product Characteristics. http:\/\/db.cbg-meb.nl\/IB-teksten\/h10305.pdf (accessed 3 Jan 2014)."},{"key":"2024051512280951000_4.11.e005602.21","first-page":"259","article-title":"NHG-standard acne","volume":"50","author":"Smeets","year":"2007","journal-title":"Huisarts Wet"},{"key":"2024051512280951000_4.11.e005602.22","unstructured":"Implementatie Bijzonder Kenmerk: \u2018Let op zwangerschapspreventieprogramma\u2019 in Z-index. 2009. https:\/\/www.z-index.nl\/g-standaard\/beschrijvingen\/functioneel\/wijzigingen\/mb\/bijzondere-kenmerken\/IR%20BK%20Zwangerschapspreventieprogramma%20V-1-1-1.pdf (accessed 3 Mar 2014)."},{"key":"2024051512280951000_4.11.e005602.23","unstructured":"College ter Beoordeling van Geneesmiddelen\/Medicines Evaluation Board (CBG\/MEB). Zwangerschapspreventie programmas (ZPP). http:\/\/www.cbg-meb.nl\/CBG\/nl\/humane-geneesmiddelen\/geneesmiddelenbew\/zwangerschapspreventieprogramma\/default.htm (accessed 3 Mar 2014)."},{"key":"2024051512280951000_4.11.e005602.24","unstructured":"Commissie Farmaceutische Hulp. Isotretino\u00efne: waarschuwingen en voorzorgen. Farmacotherapeutisch kompas. College van Zorgverzekeringen , 2007."},{"key":"2024051512280951000_4.11.e005602.25","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1111\/j.1365-2133.2010.09976.x","article-title":"Compliance with pregnancy prevention programmes of isotretinoin in Europe: a systematic review","volume":"164","author":"Crijns","year":"2011","journal-title":"Br J Dermatol"},{"key":"2024051512280951000_4.11.e005602.26","first-page":"2692","article-title":"Zwangerschapspreventie bij teratogene middelen faalt","volume":"48","author":"Fledderus","year":"2012","journal-title":"Medisch Contact"},{"key":"2024051512280951000_4.11.e005602.27","first-page":"A6567","article-title":"Pregnancy after isotretinoin use","volume":"157","author":"Manders","year":"2013","journal-title":"Ned Tijdschr Geneeskd"},{"key":"2024051512280951000_4.11.e005602.28","unstructured":"Crijns HJ. Teratogene middelen: zwangerschapspreventie kan beter. 2012. http:\/\/www.pw.nl\/nieuws\/nieuwsberichten\/2012\/teratogene-middelen-zwangerschapspreventie-kan-beter (accessed 3 Mar 2014)."}],"container-title":["BMJ Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bmjopen-2014-005602","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,15]],"date-time":"2024-05-15T19:43:09Z","timestamp":1715802189000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmjopen.bmj.com\/lookup\/doi\/10.1136\/bmjopen-2014-005602"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,11]]},"references-count":28,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2014,11,12]]},"published-print":{"date-parts":[[2014,11]]}},"alternative-id":["10.1136\/bmjopen-2014-005602"],"URL":"https:\/\/doi.org\/10.1136\/bmjopen-2014-005602","relation":{},"ISSN":["2044-6055","2044-6055"],"issn-type":[{"value":"2044-6055","type":"print"},{"value":"2044-6055","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,11]]}}}